Back to Search
Start Over
Shire Fourth-Quarter Earnings Exceed Analysts' Expectation (2).
- Source :
- Bloomberg.com; 2/11/2016, pN.PAG-N.PAG, 1p
- Publication Year :
- 2016
-
Abstract
- Shire Plc, the drugmaker that agreed to buy Baxalta Inc. for $32 billion last month, posted fourth-quarter earnings that beat analysts' estimates as it sold more drugs for attention deficit hyperactivity disorder and rare diseases. Sales of several rare disease drugs -- including Elaprase, Cinryze, Replagal and Vpriv -- missed analysts' estimates last quarter. [Extracted from the article]
- Subjects :
- ATTENTION-deficit hyperactivity disorder
CHIEF financial officers
Subjects
Details
- Language :
- English
- Database :
- Complementary Index
- Journal :
- Bloomberg.com
- Publication Type :
- Periodical
- Accession number :
- 140531601